Loading…
Develops psilocybin-based therapy (COMP360) combined with psychological support for treatment-resistant depression.
Develops psilocybin-based therapy (COMP360) combined with psychological support for treatment-resistant depression.
Has no product to sell yet, so it is funded by share sales, and its value rests on getting COMP360 approved and then paid for by insurers. The treatment is a supervised dosing session with trained therapists rather than a pill taken at home, so a launch would need clinics set up for it. The company is based in London.
Moat: narrow (IP / patents, regulatory licence). First mover with patented synthetic psilocybin formulation and specialized therapy-delivery infrastructure.
Headquarters: London, UK · Founded: 2016 · Employees: 156
Size COMPASS Pathways Plc Sponsored ADR (CMPS) is a United States Health Care company (Biotechnology) with a market value of $1.22B, the 2131st largest of 3,117 United States companies the cockpit tracks. Shares closed at $8.61 on 6 Nov 2026.
Performance Over six months the shares fell 13.1%, against -10.3% for the median peer and -1.1% for the United States market (cap-weighted) — 10th lowest of 20 in its peer set.
Short interest Short interest is 12.8% of the free float (15 Oct 2026).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$5,991 | -$216,505 | -$233,098 | -$242,938 | -$329,796 |
| EBITDA | -$198M | -$179M | -$178M | -$137M | -$110M |
| Net income | -$280M | -$289M | -$155M | -$119M | -$91.4M |
| Free cash flow | -$177M | -$158M | -$119M | -$97.8M | -$106M |
| Capital expenditure | $0 | $0 | $0 | $66,256 | $595,632 |
| Total debt | $54.4M | $35.0M | $32.2M | $33.0M | $1.93M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| COMPASS Pathways Plc Sponsored ADR CMPS | $1.22B | -13% | n/a | n/a | n/a | n/a |
| AtaiBeckley ATAI | n/a | +81% | n/a | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CMPS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -24.9% | -3.5% | 4th lowest of 21 |
| 6-month return | -13.1% | -10.3% | 10th lowest of 20 |
| Distance from 52-week high | -45.8% | -40.7% | 7th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| COMPASS Pathways Plc Sponsored ADR CMPS | United States | $1.22B | -13% | n/a | n/a | n/a | n/a | n/a |
| Vor Biopharma VOR | United States | $1.22B | +17% | n/a | n/a | n/a | n/a | n/a |
| Akums Drugs and Pharmaceuticals AKUMS.NS | India | $1.22B | +34% | +18% | 10% | 2.1× | 15.8% | +9.9% |
| UroGen Pharma URGN | United States | $1.21B | -16% | +159% | -12% | 5.2× | n/a | n/a |
| Duality Biotherapeutics 9606.HK | Hong Kong | $1.23B | -60% | -5% | -181% | 7.0× | n/a | n/a |
| SpyGlass Pharma SGP | United States | $1.24B | +58% | n/a | n/a | n/a | n/a | n/a |
| Inhibrx Biosciences INBX | United States | $1.24B | -37% | -100% | n/a | n/a | n/a | n/a |
| Rapport Therapeutics RAPP | United States | $1.17B | -36% | n/a | -838% | 39.3× | n/a | n/a |
| Liaoning Chengda Biotechnology 688739.SS | China | $1.28B | -10% | -9% | 0% | 2.5× | 8.8% | -7.0% |
| Guangzhou Wondfo Biotech 300482.SZ | China | $1.14B | -10% | -24% | -2% | 3.2× | 16.4% | -5.8% |
| Daan Gene 002030.SZ | China | $1.11B | -9% | +1% | -81% | 8.4× | 5.7% | -32.3% |
| Mineralys Therapeutics MLYS | United States | $1.36B | -48% | n/a | n/a | n/a | n/a | n/a |
| Janux Therapeutics JANX | United States | $1.08B | +24% | +5,367% | -598% | 5.3× | n/a | n/a |
| Pacific Shuanglin Bio-pharmacy 000403.SZ | China | $1.38B | -19% | +1% | 10% | 3.8× | n/a | n/a |
| Oncolys BioPharma 4588.T | Japan | $1.39B | +162% | +1,662% | -303% | 429.8× | n/a | n/a |
| AnaptysBio ANAB | United States | $1.39B | -33% | +93% | 56% | 6.3× | -1.2% | +25.6% |
| Hualan Biological Vaccine 301207.SZ | China | $1.39B | -21% | -28% | -7% | 10.3× | 36.5% | -13.1% |
| Taysha Gene Therapies TSHA | United States | $1.41B | -36% | -32% | -2,855% | 184.6× | n/a | n/a |
| Korsana Biosciences KRSA | United States | $1.41B | +43% | -13% | -359% | 743.5× | n/a | n/a |
| Kardigan KARD | United States | $1.45B | n/a | n/a | n/a | n/a | n/a | n/a |
| Verastem VSTM | United States | $1.02B | +72% | +3,996% | -183% | 11.1× | n/a | n/a |